Decision to list Interventional Radiology products supplied by Edwards Lifesciences (New Zealand) Limited

Hospital devices Decision

We’re pleased to announce the approval of a listing agreement for Interventional Radiology products with Edwards Lifesciences (New Zealand) Limited.

In summary this will result in a range of embolectomy catheters being listed in Part III of Section H of the Pharmaceutical Schedule from 1 February 2019.

This Agreement would supersede any existing DHB contracts with these suppliers for the devices listed in Schedule One of the Agreement. 

The list of Edward’s Interventional Radiology products will be available on PHARMAC's website from 1 February 2019, in both a PDF document and an Excel spreadsheet.

Any changes to the original proposal?

This decision was subject to consultation with a letter dated 12 November 2018. No changes were made to the listing agreement as a result of consultation feedback.

Who we think will be most interested

  • DHB staff
    • Interventional radiology clinical staff
    • Procurement Officers
  • Suppliers and Wholesalers

Detail about this decision

In September 2017 PHARMAC issued a Request for Proposals (“RFP”) for interventional radiology products for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

After completing the RFP evaluation, and consulting on the provisional agreement reached with Edwards, PHARMAC has decided to list Edward’s ranges of Interventional Radiology Products in Part III of Section H of the Pharmaceutical Schedule from 1 February 2019.

DHBs that purchase Edward’s Interventional Radiology Products must do so under the terms and conditions, and at the prices, included in the Agreements, from 1 February 2019.

DHBs can continue to choose which Interventional Radiology Products they purchase.

Edward’s products are the most recent Interventional Radiology products that PHARMAC has decided to list on the Pharmaceutical Schedule. The remaining consultations in this category are expected over the next few months.

Our response to what you told us

We’re really grateful for the time people took to respond to this consultation. A summary of the main themes raised in feedback and our responses to the feedback received are set out below:


PHARMAC Staff Comment

Advising that no technical or resource impacts are anticipated as a result of Endoventure, Boston and Terumo’s proposals


If you have any questions about this decision, you can email us at; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.